

# Evaluation of Prepared formulation and hydroalcoholic extract of *Carica papaya* leaf for *in vitro* cytotoxicity activity on Human Liver Carcinoma (HEPG2) cell line

**Rinu Rana\*<sup>1</sup>, Mahendra Singh Ashawat<sup>2</sup>**

<sup>1</sup> Research Scholar, Himachal Pradesh Technical University, Hamirpur, off campus Research centre, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Kangra, Himachal Pradesh, India

<sup>2</sup> Director cum Principal, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Kangra, Himachal Pradesh, India

**Corresponding author:**

**Rinu Rana**

Research Scholar, Himachal Pradesh Technical University, Hamirpur, off campus Research centre, Laureate Institute of Pharmacy, Kathog, Jawalamukhi, Kangra, Himachal Pradesh, India- 176031

**[rinupharma@gmail.com](mailto:rinupharma@gmail.com)**

## **Abstract**

*Carica papaya* (papaya) of Caricaceae family is a well-known medicinal plant which is being used traditionally for immunomodulatory, anti-sickling and anti-thrombocytopenic property. It is an evergreen herbaceous tree originated from Central America. It is reported to have carbohydrates, amino acids, saponin glycosides, flavonoids, phenolics, tannins and alkaloids. In present study, phytosomes of hydroalcoholic extract of *Carica papaya* leaves is prepared and assessed for their *in vitro* cytotoxicity activity by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay on Human Liver Carcinoma (HEPG2) cell line. The performance of prepared formulation is compared with conventional preparation i.e. hydroalcoholic extract. From the results, it was concluded that the novel formulation of hydroalcoholic extract of *Carica papaya* leaves is more effective than extract.

**Keywords:** *Carica papaya*, phytosomes, MTT assay, HEPG2 cell line

## Introduction

Cancer is a disease which is caused by ruthless growth of abnormal cells. It leads to aggregation of cells and forms tumours in the body. It is distributed worldwide with high mortality rate. One of the major reasons for the disease is damage by free radical, which further leads to damage of Deoxyribonucleic acid (DNA), lipids and proteins and results in mutations. Mutation results in conversion of normal cells into cancer cells<sup>1-5</sup>.

## Liver cancer

Liver diseases are the major causes for the deaths in India. Liver cancer is the second in terms of mortality due to cancer. The treatments used for the treatment of liver cancer are radiation therapy, anti-hormonal therapy, liver resection and chemotherapy. These treatments on longer term produce various side effects. These anti-cancer therapy causes cytotoxicity which destroys cancer cells along with normal cells. Therefore, it is need of the hour to find an alternative solution to this with no or minimum side effects. To overcome this situation, the use of traditional herbal medicine is screened out for anticancer effects<sup>6-10</sup>.

## Hepatocellular cancer

HepG2 cell line is an immortalized cell line. It is produced from Caucasian male liver tissue. HepG2 cell line consists of carcinoma cells of human liver. It has 55 chromosomal pairs and it is grown at a higher scale. According to study, around 630,000 new cases of Hepatocellular carcinoma are diagnosed every year making it the most common cancer in the world. The major reasons for Hepatocellular carcinoma are infections of Hepatitis B, Hepatitis C and alcohol-induced liver injury<sup>11-21</sup>.

Nowadays, there is great demand of herbal products for liver diseases in the people because of increased awareness for health benefits. But they have poor bioavailability in case of hydrophilic natured phytoconstituents. Hence, incorporation of these hydrophilic herbal drugs in a lipophilic carrier system will increase their permeability, bioavailability and thus better therapeutic effect. Phytosomes are novel formulation formed by complexation with phospholipids. They have better stability in the gastric environment and increase the bioavailability of herbal drug<sup>22-26</sup>. Nanotechnology has opened new possibilities in medical sciences. It offers a novel and efficacious approach to formulate bioenhanced anticancer formulations.

## *In vitro* study

### MTT Assay

In latest studies MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay is considered to be reliable for quantification of cell viability. MTT is a yellow coloured water soluble tetrazolium salt. The living cells which are metabolically active convert this salt to dark blue formazan crystals which is water insoluble. Therefore the number of living cells can be calculated by amount of formazan produced and it is directly proportional.

### ***Carica papaya***

*Carica papaya* is economically important plant cultivated globally for their fruit. The phytochemical investigation proves the presence of carbohydrates, amino acids, saponin glycosides, flavonoids, phenolics, tannins and alkaloids. All parts of *Carica papaya* has well known. The health benefit of all parts of *Carica papaya* is well known and considered worldwide<sup>27-54</sup>.

### **Materials and methods**

Chemicals like MTT, Trypsin – EDTA, Antibiotics and DPBS were procured from HiMedia, India. Fetal Bovine Serum (FBS) and DMEM-HG (Dulbecco's Modified Eagle Medium-high glucose) were purchased from Gibco, Brazil and Gibco, USA respectively. Dimethylsulfoxide (DMSO) was purchased from SDFCL, India. Ethanol, chloroform, phosphatidylcholine and cholesterol were purchased from Merck. All chemicals used were of analytical grade.

Biosafety Cabinet (Ascension, India), Carbon dioxide Incubator (NuAire, USA), Inverted tissue culture microscope (Nikon, Japan) and Automated micro plate reader (Biotek, USA) were used during the experiment.

### **Preparation of extract**

The leaves of *Carica papaya* were collected from a local area of Kangra district (Himachal Pradesh), India in the month of August, 2020 depending upon its easy availability. The leaves were authenticated by Dr. Anjula Pandey, principal scientist at ICAR- National Bureau of Plant Genetic Resources, National Herbarium of cultivated plants, New Delhi against a voucher specimen NHCP/NBPGR/2013-24, NHCP/NBPGR/2013-25, NHCP/NBPGR/2013-23. The leaves were thoroughly washed with water to remove the impurities and air dried.

The fresh leaves of *Carica papaya* were macerated with hydroalcoholic mixture for 24 hours with occasional shaking. The extracts were then filtered and concentrated to dryness. The resultant extracts were stored for further study.

### **Preparation of phytosomes**

The phytosomes of hydroalcoholic extract of *Carica papaya* leaves was prepared by rotary evaporator method. Accurately weighed quantity of phosphatidylcholine, hydroalcoholic extract of *Carica papaya* leaves and cholesterol were dissolved in 10 ml of chloroform in round bottom flask (RBF) and dehydration of organic solvent was done by Rotary evaporator. After complete removal of solvent thin layer of phospholipids mixture was formed. This film was rehydrated with phosphate buffer 7.4. After hydration, mixture was sonicated for 20 minutes. The prepared phytosomes were stored in freezer (2-8°C) until further use.

The *in vitro* MTT assay was performed to determine the level of cytotoxicity for the test substances on Human Liver Carcinoma (HEPG2) cell line.

### **Preparation of test substances for cytotoxicity screening**

10 mg of test substances were weighed separately and made up with DMEM-HG medium (Dulbecco's Modified Eagle Medium-high glucose) supplemented with 2% inactivated FBS

to obtain a stock solution of 10 mg/mL. Furthermore, serial two-fold dilutions were prepared from the stock solution to prepare lower concentrations for cytotoxicity testing.

### Cell line and culture medium


Human Liver Carcinoma (HEPG2) cell line was procured from NCCS, India. Stock cells were cultured in DMEM-HG (Dulbecco's Modified Eagle Medium-high glucose) supplemented with 10% inactivated Fetal Bovine Serum (FBS), penicillin (100 IU/mL), streptomycin (100 µg/mL) and amphotericin B (5 µg/mL) in an humidified atmosphere of 5% CO<sub>2</sub> at 37°C until confluent. The cells were dissociated with TPVG solution (0.2% Trypsin, 0.02% EDTA, 0.05% glucose in PBS). The stock cultures were grown in 25 cm<sup>2</sup> culture flasks and cytotoxicity studies were carried out in 96-well micro titre plate (Tarsons India Pvt. Ltd., Kolkata, India).

### Determination of cell cytotoxicity by MTT Assay

The cell culture monolayer was trypsinized and the cell count was adjusted to 1,00,000 cells/mL using DMEM-HG containing 10% FBS. To each well of the 96-well micro titre plate, 0.1 mL of the diluted cell suspension was added. After 24 h, when a partial monolayer was formed, the supernatant was flicked off, the monolayer was washed once with DPBS (Dulbecco's Phosphate Buffered Saline) and different test concentrations were added in the micro titre plate. The untreated cells were maintained as cell control for comparison. The plate was then incubated at 37°C for 24 h in 5% CO<sub>2</sub> atmosphere. After 24 h, microscopic examination was carried out and observations were noted, the test solutions in the wells were discarded and 100 µL of MTT diluted with DPBS was added to each well. The plate was gently shaken and incubated for 3 h at 37°C in 5% CO<sub>2</sub> atmosphere. The supernatant was removed and 100µL of DMSO was added and the plate was gently shaken to solubilize the formed formazan. The absorbance was measured using a micro plate reader at a wavelength of 570 nm<sup>55</sup>.

## RESULTS

Table 1: Analysis of the *in vitro* cytotoxicity of the test substances against Human Liver Carcinoma (HEPG2) cell line by MTT assay



## DISCUSSION AND CONCLUSION

Test substances were assayed for *in vitro* cytotoxicity study against Human Liver Carcinoma (HEPG2) cell line by exposing the cells to different concentrations ranging from 125µg/ml to 7.8µg/ml. MTT assay was employed to test the cytotoxic effect of selected concentrations of given test substances on Human Liver Carcinoma (HEPG2) cell line by measuring the metabolic activity through a colorimetric determination. The MTT assay is usually carried out to detect the cells with constant mitochondrial activity, thereby an increase or decrease in the number of viable cells is linearly related to mitochondrial activity. The CTC<sub>50</sub> of hydroalcoholic extract of *Carica papaya* leaves were >300 µg/mL and for phytosomes of hydroalcoholic extract of *Carica papaya* leaves were found to be <200µg/mL on Human Liver Carcinoma (HEPG2) cell line. Therefore, the given test substances (hydroalcoholic extract and phytosomes of *Carica papaya* leaves) were considered to be cytotoxic in Human Liver Carcinoma (HEPG2) cell line.

The present study showed that phospholipid complex of *Carica papaya* leaf has better therapeutic efficacy at low concentration as compared to the extract itself because of its improved release property. Hence, better results were obtained for phytosomes of *Carica papaya* leaf at laboratory scale.

The study also indicates that there is an ample scope of using *Carica papaya* leaf as phospholipid complex in the management of liver ailments. However, further studies are required to implement this treatment technique to humans. Therefore, long term *in vivo* toxicity studies as per OECD (The Organisation for Economic Co-operation and Development guidelines) for phytosomes as well as clinical trial studies may be considered in future.

## References

1. Meacham C.E., Morrison S.J., Tumour heterogeneity and cancer cell plasticity, Nature 2013, 501: 328-337.
2. Fisher R., Pusztai L., Swanton C., Cancer heterogeneity: implications for targeted therapeutics, British Journal of Cancer 2013, 108: 479-485.
3. Schottenfeld D., Fraumeni Jr. J.F., Cancer Epidemiology and Prevention, Oxford University Press 2006.
4. Yoo K.Y., Shin H.R., Cancer epidemiology and prevention, Korean Journal of Epidemiology 2003, 25: 1-15
5. Roszkowski, K., Zurawski, B., Jozwicki, W. et al. Impact of Specific KRAS Mutation in Exon 2 on Clinical Outcome of Chemotherapy- and Radiotherapy-Treated Colorectal Adenocarcinoma Patients. Molecular Diagnosis & Therapy 2014, 18: 559–566.
6. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. The Lancet 2012; 379:1245–55.
7. Forner A, Gilibert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nature Reviews Clinical Oncology 2014; 11:525–35.
8. Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. Revista da Associacao Medica Brasileira. 2013; 59:514–524.

9. Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? *World Journal of Experimental Medicine* 2016; 6:21–36.
10. McGlynn K, London W.T., The global epidemiology of hepatocellular carcinoma, present and future. *Clinics in Liver Disease* 2011; 15:1–22.
11. Abreu RM, Ferreira CS, Nasser PD, et al. Hepatocellular Carcinoma: The final moments of life. *Journal of Cancer Therapy* 2013;4:377–83.
12. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology*. 2011; 53:1020–1022.
13. Cervello M, McCubrey JA, Cusimano A, et al. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. *Oncotarget*. 2012; 3:236–60.
14. De Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. *Journal of Hepatology* 2012; 56:75–87.
15. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology*. 2012; 142:1264–73.
16. Thyagarajan, S. P., Jayaram, S., Gopalakrishnan, V., Hari, R., Jeyakumar, P. & Sripathi, M. S.. Herbal medicines for liver diseases in India. *Journal of Gastroenterology and Hepatology* 2002, 17: S370-S376.
17. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. & Forman, D. 2011. Global cancer statistics. *CA: a cancer journal for clinicians*, 61, 69-90.
18. Papatheodoridis, G. V., Lampertico, P., Manolakopoulos, S. & Lok, A. 2010. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. *Journal of hepatology*, 53, 348-356.
19. Roncalli, M., Terracciano, L., Di Tommaso, L., David, E. & Colombo, M. 2011. Liver precancerous lesions and hepatocellular carcinoma: the histology report. *Digestive and Liver Disease*, 43, S361-S372.
20. Herrera, S. & Bruguera, M. 2008. Hepatotoxicidad inducida por el uso de hierbas y medicamentos para perder peso. *Gastroenterología y hepatología*, 31, 447-453.
21. Karandikar, S., Joglekar, G., Chitale, G. & Balwani, J. 1963. Protection by indigenous drugs against hepatotoxic effects of carbon tetrachloride-a long term study. *Acta Pharmacologica et Toxicologica*, 20, 274-280.
22. Singha, A., Saharanb, V. A., Singha, M. & Bhandaria, A. 2011. Phytosome: Drug Delivery System for Polyphenolic Phytoconstituents. *Iranian Journal of Pharmaceutical Sciences*, 7, 209-219.
23. Yan-yu, X., Yun-mei, S., Zhi-peng, C. & Qi-neng, P. 2006. Preparation of silymarin proliposome: a new way to increase oral bioavailability of silymarin in beagle dogs. *International Journal of Pharmaceutics*, 319, 162-8.
24. Bankey, P., Beecherl, E., Bibus, D., See, D. & McIntyre, K. 1995. Liposomes modulate Kupffer cell endotoxin response. *The Archives of Surgery*, 130, 1266-72.
25. Moghimi, S. M., Parhamifar, L., Ahmadvand, D., Wibroe, P. P., Andresen, T. L., Farhangrazi, Z. S. & Hunter, A. C. 2012. Particulate systems for targeting of macrophages: basic and therapeutic concepts. *Journal of Innate Immunity*, 4, 509-28.
26. El-Samaligy, M. S., Afifi, N. N. & Mahmoud, E. A. 2006. Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. *International Journal of Pharmaceut*, 319, 121-129.

27. Duke, J.A., 1983. Handbook of Energy Crops (unpublished). Duke, J.A., 1983. Handbook of Energy Crops (unpublished). Purdue University, Centre for New Crops & plants products, West Lafayette, Indiana.
28. Teixeira, Rashid, Z., Nhut, D.T., Sivakumar, D., Gera, A., Teixeira, M., Tennant, P.F., 2007. Papaya (*Carica papaya* L.) Biology and Biotechnology. Tree and Forestry Science and Biotechnology 1, 47–73.
29. Zunjar, V., Mammen, D., Trivedi, B.M., Daniel, M., 2011. Pharmacognostic, Physicochemical and Phytochemical Studies on *Carica papaya* Linn. Leaves. Pharmacognosy Journal 3, 05–08. doi:10.5530/pj.2011.20.2
30. Krishna, K.L., Paridhavi, M., Patel, J. a, 2008. Review on nutritional , medicinal and pharmacological properties of Papaya ( *Carica papaya* Linn .). Natural Product Radiance 7, 364–373. doi:0975-6299
31. Gupta NK, Bansal SB, Jain UC, Sahare K. Study of thrombocytopenia in patients of malaria. Tropical parasitology. 2013, 3(1):58-63.
32. Hewitt, H., Whittle, S., Lopez, S., Bailey, E. et al., Topical use of papaya in chronic skin ulcer therapy in Jamaica. West Indian Medical Journal 2000, 49: 32–33.
33. Lim, T., Edible Medicinal and Non-Medicinal Plants: Volume 1, Fruits, Springer Science Business Media, New York 2012, 693–717.
34. Lucas, T. P. The Most Wonderful Tree in the World, the Papaw Tree (*Carica papaia*), Carter-Watson, Brisbane 1993.
35. Caninia A, Alesiania D, D’Arcangelob G, Tagliatestab P. Gas chromatographymass spectrometry analysis of phenolic compounds from leaf. Journal of Food Composition and Analysis 2007, 20: 584-590.
36. Seigler DS, Pauli GF, Nahrstedt A, Leen R. Cyanogenic allosides and glucosides from *Passiflora edulis* and *Carica papaya*. Phytochemistry 2002, 60: 873-882.
37. Oduola, T., Adeniyi, F. A. A., Ogunyemi, E. O., Bello, I. S. et al., Antisickling agent in an extract of unripe pawpaw (*Carica papaya*): is it real? African Journal of Biotechnology. 2006, 5: 1947– 1949.
38. Gunde, M. C., & Amnerkar, N. D. Nutritional, medicinal and pharmacological properties of papaya (*Carica papaya* Linn.): a review. Journal of Innovations in Pharmaceuticals and Biological Sciences, 2016, 3(1): 162- 169.
39. Amenta, R., Camarda, L., Di Stefano, V., Lentini, F. et al. Traditional medicine as a source of new therapeutic agents against psoriasis. Fitoterapia 2000, 71: S13–S20.
40. Wang, S., Meckling, K. A., Marcone, M. F., Kakuda, Y. et al. Can phytochemical antioxidant rich foods act as anti cancer agents? Food Research International 2011, 44: 2545– 2554.
41. Parle, M. Gurditta, Basketful benefits of papaya. International Research Journal of Pharmacy 2011, 2: 6–12.
42. Singh, D., Jaiswal, P., Kumar, P., Singh, V. *Carica papaya* Linn: a potential source for various health problems. Journal of Pharmacy Research 2010, 3: 998–1003.
43. Thanaraj, T., Terry, L. A. Tropical Fruit Banana, Pineapple, Papaya and Mango, Cabi, Wallingford 2011

44. Srikanth, G., Babu, S. M., Kavitha, C. H. N., Rao, M. E. B. et al. Studies on in-vitro antioxidant activities of *Carica papaya* aqueous leaf extract. Research Journal of Pharmaceutical, Biological and Chemical Sciences 2010, 1: 59–65.
45. Vijay, K., Sriram, S. Antioxidant activity of seed extracts of *Annona squamosa* and *Carica papaya*. Nutrition and Food Science 2010, 40: 403–408.
46. Mi Hee, Y., Sung Gyu, L., Hyo Gwon, I., In-Gyeong, C. et al. Antioxidant capacity and quinone reductase activity of methanol extracts and fractions from papaya seed. Korean Journal of Life Science 2011, 21: 775–782.
47. Oloyede, O., Franco, J., Roos, D., Rocha, J. et al. Antioxidative properties of ethyl acetate fraction of unripe pulp of *Carica papaya* in mice. Journal of Microbiology, Biotechnology and Food Sciences 2011, 1: 409–425.
48. Tang, C. S. Benzyl isothiocyanate of papaya fruit. Phytochemistry 1971, 10: 117–121.
49. Pierson, J. T., Dietzgen, R. G., Shaw, P. N., RobertsThomson, S. J. et al. Major Australian tropical fruits biodiversity: bioactive compounds and their bioactivities. Molecular Nutrition and Food Research 2011, 56: 357–387.
50. Sathasivam K, Ramanathan S, Mansor SM, Haris MRMH, Wernsdorfer WH. Thrombocyte counts in mice after the administration of papaya leaf suspension. Wien Klin Wochenschr. 2009, 121(3):19-22.
51. Nayak, B. S., Pereira, L. P., Maharaj, D. Wound healing activity of *Carica papaya* L. in experimentally induced diabetic rats. Indian Journal of Experimental Biology 2007, 45(8):739-743.
52. Imaga, N. A., & Adepoju, O. A. Analyses of antisickling potency of *Carica papaya* dried leaf extract and fractions. Journal of Pharmacognosy and Phytotherapy, 2010, 2(7): 97-102.
53. Nguyen TT, Parat M-O, Shaw PN, Hewavitharana AK, Hodson MP. Traditional aboriginal preparation alters the chemical profile of *Carica papaya* leaves and impacts on cytotoxicity towards human squamous cell carcinoma. PloS one. 2016, 11(2): e0147956
54. Otsuki, N., Dang, N. H., Kumagai, E., Kondo, A., Iwata, S., & Morimoto, C. Aqueous extract of *Carica papaya* leaves exhibits anti-tumor activity and immunomodulatory effects. Journal of ethnopharmacology 2010, 127(3): 760–767.
55. Francis D and Rita L. “Rapid colorimetric assay for cell growth and survival modifications to the tetrazolium dye procedure giving improved sensitivity and reliability”. Journal of Immunological Methods, 1986; 89: 271-277.